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Abstract: Melanoma is the most aggressive and deadly type of skin cancer. Surgical resection 
with or without lymph node sampling is the standard of care for primary cutaneous melanoma. 
Adjuvant therapy decisions may be informed by careful consideration of prognostic factors. 
High-dose adjuvant interferon alpha-2b increases disease-free survival and may modestly 
improve overall survival. Less toxic alternatives for adjuvant therapy are currently under 
study. External beam radiation therapy is an option for nodal beds where the risk of local 
recurrence is very high. In-transit melanoma metastases may be treated locally with surgery, 
immunotherapy, radiation, or heated limb perfusion. For metastatic melanoma, the options 
include chemotherapy or immunotherapy; targeted anti-BRAF and anti-KIT therapy is under 
active investigation. Standard chemotherapy yields objective tumor responses in approximately 
10%–20% of patients, and sustained remissions are uncommon. Immunotherapy with high-
dose interleukin-2 yields objective tumor responses in a minority of patients; however, some of 
these responses may be durable. Identification of activating mutations of BRAF, NRAS, c-KIT, 
and GNAQ in distinct clinical subtypes of melanoma suggest that these are molecularly distinct. 
Emerging data from clinical trials suggest that substantial improvements in the standard of care 
for melanoma may be possible.
Keywords: melanoma, resection, immune modulation, small molecule kinase inhibitors, 
chemotherapy, clinical trials
Introduction
Melanoma is an aggressive and often fatal type of cancer that arises from transformed 
melanocytes. These long-lived pigment-producing cells typically colonize the basal epi-
dermis during embryonal development. The incidence of melanoma has been increasing 
at a steady rate over the last 8 decades: last year over 60,000 patients were diagnosed 
in the US and over 8,000 died from this disease.1 While the increase can be attributed 
in part to increased awareness and screening, there are indications that melanoma has 
become more common. Epidemiologic studies have shown  association with a previous 
history of blistering sunburns, especially in childhood, and to a lesser extent with total 
ultraviolet exposure from all sources including tanning beds. The risk of developing 
melanoma is also increased in subjects who have many melanocytic nevi (moles), 
ie, benign proliferations of neoplastic melanocytes, and those with freckles and red 
hair, traits associated with germline polymorphisms in the melanocortin 1 receptor.
The clinical pathologic features of melanoma vary with the anatomic site in 
which it originates, which has led to the distinction of “histogenetic” subtypes of 
melanoma.2 Data from genetic analyses have confirmed the existence of distinct 
© 2010 Algazi et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
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subtypes with characteristic genetic alterations depending 
on anatomic site and degree of sun-exposure.3,4 In addition 
to the skin, melanocytes are also present in leptomeninges, 
mucous membranes, and in the uvea of the eye and can 
occasionally give rise to melanoma. Unlike melanomas 
occurring on the sun-exposed skin, which are most com-
mon in Caucasians, melanomas arising from sites such as 
the palms and soles and nail beds (acral melanomas) and 
melanomas originating from mucous membranes of the 
oropharynx, nasopharynx or anogenital region or rectum 
(mucosal melanomas) show similar incidence in Asians, 
Africans, and Caucasians. In addition to their anatomic 
location in sun-protected sites which makes UV-radiation an 
unlikely etiologic factor, these two types also show distinct 
genetic features indicating that they are distinct categories. 
Uveal melanoma arises from melanocytes in the choroid, 
the iris, or the ciliary body and also has unique genetic and 
clinical features.
The management of melanoma depends greatly on the 
location, depth and stage at presentation. In this review, 
we describe current paradigms for the management of 
melanoma.
Surgical excision of the primary 
cutaneous melanoma
wide local excision with 1 to 2 cm 
margins is the standard of care
Surgical excision is the primary treatment for cutaneous 
melanoma. Optimal surgical margins depend on the thickness 
of the primary melanoma lesion. Three large trials examin-
ing excision margins for melanomas 2 mm or thinner in 
depth showed no significant difference in nodal recurrence, 
distant metastasis, disease-free survival, or overall survival 
after local excision when margins of 1 cm margins were 
compared to 3 cm margins5,6 or when 2 cm were compared 
to 5 cm margins.7,8 Similarly, a trial examining surgical 
margins for primary melanoma lesions of intermediate 
thickness (1 to 4 mm) showed no significant difference in 
recurrence between patients undergoing excisions with 2 or 
4 cm margins, but, significantly more patients in the 4 cm 
margin group required skin grafting (46% compared to 11% 
in the 2 cm margin group). In contrast, a British trial examin-
ing excision margins in melanomas greater than 2 mm thick 
demonstrated an increased rate of locoregional recurrence 
after excision with 1 cm margins in comparison with 3 cm 
margins.9 There are no large prospective randomized trials 
examining excision margins for thick melanomas (greater 
than 4 mm in thickness), but a retrospective study of 278 
patients with melanomas greater than 4 mm thick showed 
that margins greater 2 cm did not improve the rates of local 
recurrence, disease-free survival, or overall survival.10 
Based on these data, at our institution, we recommend 1 cm 
surgical margins for invasive melanomas #1.0 mm thick, 
1 to 2 cm margins for melanomas between 1.01 and 2.0 mm 
in thickness, and 2 cm margins for melanomas thicker than 
2.0 mm.11
Staging and risk stratification
Once a melanoma has been excised, the pathologic charac-
teristics of the lesion can be used for risk stratification. In 
addition, lymph nodes may also be available for evaluation. 
A primary goal of staging is to identify prognostic factors, 
which give insight into a given patient’s expected clinical 
course, and potentially, predictive factors, which help to 
identify patients who are most likely to benefit from  adjuvant 
therapy.
Risk stratification based on tumor 
pathology
The TNM staging system for node negative melanoma is 
based on survival data from more than 27,000 stage I and II 
melanoma patients. These data identified primary tumor 
thickness (also known as Breslow depth), ulceration, and 
a mitotic rate higher than 1/mm2 as factors associated with 
worse survival.12 For example, primary tumor thickness 
was a strong predictor of survival, and 92% of patients with 
node negative, T1 (,1 mm thick) melanoma primary tumors 
 survived 10 years compared with only 50% of patients 
with node negative T4 (.4 mm thick) tumors. The new 
staging guidelines from the American Joint Committee on 
Cancer (AJCC) also identify primary tumor ulceration as 
an  independent prognosticator of survival,12 and in a pooled 
meta-analysis of three large adjuvant interferon trials E1684, 
E1690, and E1694, primary tumor ulceration was associ-
ated with worse relapse-free survival (RFS, HR = 1.54) and 
 overall survival (OS, HR = 1.73).13 Interestingly, post-hoc 
analysis of two large European trials, EORTC 18952 and 
EORTC 18991, also suggested that patients with ulcer-
ated primary lesions, particularly those with no more than 
minimal nodal metastases, may benefit more from treatment 
with adjuvant interferon than patients with non-ulcerated 
primary lesions. In these patients, interferon substantially 
decreased the risk of relapse by 25%, the risk of developing 
distant metastasis by 31%, and the risk of death by 31%.14 
These data have not been validated in a randomized, pro-
spective trial.
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indications for lymph node sampling in melanoma
Lymph node sampling is commonly used in melanoma 
patients to obtain additional prognostic data that may guide 
management decisions. In the absence of palpable regional 
lymphadenopathy, the decision to proceed with lymph node 
sampling after excision of a primary melanoma lesion is 
frequently based on the pretest probability of detecting nodal 
micro-metastatic disease, which increases monotonically 
with the depth of the primary lesion. In several large clinical 
trials and meta-analyses, nodal metastases were uncommon 
in patients with melanoma primary lesions under 1 mm thick, 
with positive nodes seen in only 1% – 5.6% of patients.15,16 
In contrast, thick lesions with Breslow depths greater than 
4 mm were associated with high rates of nodal metastases 
with estimates ranging from 35.5% to 45%.15,16 Lesions of 
intermediate depth were associated with an intermediate 
probability of nodal metastasis. For example, in one study, 
the incidences nodal metastases in patients with 1–2 mm 
deep and 2–4 mm deep primary lesions were 15% and 30% 
respectively.17 Ulceration status, Clark’s level, and regres-
sion have not been found to be useful in predicting sentinel 
lymph node status.
The sentinel lymph node biopsy procedure was developed 
as a means of identifying patients with nodal metastasis 
without the morbidity associated with a complete lymph 
node dissection, and the presence and size of metastases 
in the sentinel lymph nodes are have substantial prognostic 
value. In a sentinel lymph node biopsy, a radioisotope, Tc99 
colloid, and blue dye are injected circumferentially around 
the primary melanoma site, and the location of the sentinel 
lymph node is determined using a  lymphoscintigram, a 
handheld Geiger counter, visual inspection, and confirma-
tory pathological analysis.18 Patients with negative sentinel 
lymph node biopsies rarely have evidence of metastatic 
melanoma in non-sentinel nodes (incidence #1%).18,19 Fur-
thermore, patients undergoing sentinel lymph node biopsy 
only have a much lower incidence of surgical complications, 
 including lymphedema, wound infection, and hematoma/
seroma formation, than patients undergoing complete 
regional lymph node dissections.20 In general, the presence 
of nodal melanoma metastases confers a worse overall prog-
nosis. For example, in a randomized trial of 1347 patients 
with primary  melanomas either $1 mm thick or with a 
high Clark level (IV or V), positive sentinel node biopsies 
conferred significantly worse rates of 5-year disease-free 
(53.4% compared to 83.2% for sentinel node negative 
patients) and melanoma-specific survival (72.3% compared 
to 90.2%).21 A recent retrospective analysis suggested that 
the size of nodal metastatic foci is associated with overall 
prognosis.  Specifically, 5-year  melanoma-specific survival 
rates decreased monotonically with increasing size of the 
largest nodal metastatic focus in the sentinel lymph node 
(MSS = 94% for  metastases , 0.1 mm, 70% for 0.1–1.0 mm, 
and 57% for .1.0 mm; P , 0.001). Furthermore, only 
9% of patients with minimal sentinel node disease (largest 
focus ,0.1 mm) developed distant metastases at 5 years 
follow-up.22 These data suggest that patients with mini-
mal sentinel node disease may require neither completion 
lymphadenectomy or adjuvant systemic therapy. However, 
these data have yet to be validated prospectively, and the 
revised TNM staging criteria established by the American 
Joint Committee on Cancer state that miniscule foci of nodal 
melanoma metastases detected by immunohistochemistry 
represent node positivity and warrant a designation of stage 
III disease.12
A completion lymph node dissection, radical  dissection 
of the remaining regional lymph nodes, is typically 
 recommended for further risk stratification after a positive 
sentinel lymph node finding, but the therapeutic benefit of 
this procedure is controversial.12 Several large clinical trials 
have failed to demonstrate any improvement in melanoma 
specific survival21 or overall survival in patients  undergoing 
 complete lymph node dissections.23–27 The Multicenter 
Sentinel Lymphadenectomy Trial (MSLT) did show a 
significant difference in disease-free survival (78.3% vs 
73.1% at 5 years), and a post-hoc analysis demonstrated 
improved survival in sentinel lymph node-positive patients 
who underwent immediate lymphadenectomy compared 
to patients who received delayed lymphadenectomy for 
palpable nodal metastasis in the observation group (5-year 
OS 72.3% vs 52.4%). However, these post-randomization 
subgroups are not equivalent since all patients who received 
delayed lymphadenectomy had developed palpable nodal 
disease whereas only a subset of patients of patients with 
initially microscopic nodal disease would be anticipated to 
develop palpable nodal metastases in the future. Based on 
these data, we recommend completion lymph node dissection 
when findings of the procedure will guide adjuvant therapy 
decisions or when recurrence is likely to cause physical or 
psychological morbidity.
The role of imaging in staging
The identification distant metastases in patients with  primary 
melanoma lesions significantly impacts management since 
the management and prognosis of systemic melanoma 
 differs substantially from that of local or locoregional 
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 disease.  However, based on the pre-test probability of 
 finding  metastatic lesions, whole body imaging with a CT or 
PET/CT scan is appropriate only for patients with regional 
nodal metastases. CT imaging detects occult disease in 
0.5%–3.7% of patients28–31 with microscopic nodal metastases 
on sentinel lymph node biopsy and in 4%–16% of patients 
with clinically palpable nodal disease.31–34 In contrast, only 
one true metastatic lesion was identified in a total of over 500 
patients with invasive, node-negative melanoma evaluated in 
two large studies.35,36 Thus, available data do not support the 
routine use of imaging in initial staging of clinically node-
negative melanoma.
Adjuvant (post-operative) therapy 
for high risk melanoma
Radiation therapy
External beam radiation is most commonly used in patients 
with resected nodal metastases to prevent local recurrence 
in the irradiated nodal basin. A recent randomized trial 
examined a total external beam radiation dose of 48 Gy 
in 20 daily fractions versus no treatment in 248 patients 
with resected, high-risk, node-positive melanoma. Radia-
tion therapy decreased the incidence of in-field relapse 
(35% vs 18%, P , 0.005) without impacting the inci-
dence of distant metastases. There was also a concerning 
trend toward decreased overall survival in patients treated 
with radiation compared with patients randomized to 
observation (overall survival 2.6 vs 3.9 years).37 Thus, 
external beam  radiation may be most appropriate when 
local recurrence would be associated with a high degree 
of morbidity.
interferon alpha-2b
Treatment with high doses of adjuvant interferon in  high-risk 
stage II and stage III melanoma reduced the risk or disease 
recurrence and increased the median disease-free survival 
in several large trials. The ECOG trial E1684 (1996) 
 established a high dose interferon regimen that remains 
the standard of care today for adjuvant therapy in high 
risk stage II and stage III melanoma.38 In the trial, patients 
 randomized to the  interferon arm received doses of 20 
MIU/m2/day  intravenously for 1 month then 10 MIU/m2 
3 times per week subcutaneously for 48 weeks. Adjuvant 
interferon increased the median relapse-free survival from 
1 to 1.7 years (P = 0.0023, one-sided) and overall survival 
from 2.8 to 3.8 years (P = 0.0237, one-sided) compared 
with  observation. Common grade 3 and 4 toxicities included 
bone marrow suppression, hepatotoxicity, fatigue, flu-like 
symptoms, and neuropsychiatric disturbances. However, 
while dose modifications were necessary in the majority of 
patients, most patients were able to tolerate 80% or more 
or the scheduled dose. Several trials have demonstrated 
improvements in relapse-free survival using lower doses of 
interferon,39–41 but such doses appear to be less  effective. 
In one head-to-head comparison, the E1694 regimen 
 significantly increased the rate of 5-year relapse-free survival 
versus placebo (44% vs 35%, P = 0.05) while low-dose 
interferon, 3 MIU subcutaneously daily 3 times per week, did 
not (5-year relapse-free survival 40% vs 35%, P = 0.17).42 
A meta-analysis of several trials, including ECOG trials 
E1684, E1690, and E1694, also demonstrated that high-dose 
interferon regimens increase the duration of relapse-free 
survival, but adjuvant interferon conferred only a small 
overall survival benefit in this meta-analysis.13
Several trials have examined the optimal duration of 
adjuvant interferon therapy. The Hellenic Cooperative 
Oncology Group compared a 4-week intravenous inter-
feron regimen with and without 48 weeks of subsequent 
subcutaneous interferon and demonstrated no significant 
difference in the relapse-free survival between the two treat-
ment groups.43 Furthermore, it was noted that the patients 
treated for only 4 weeks were less likely to suffer significant 
adverse effects including hepatotoxicity, nausea/vomiting, 
alopecia, and neurologic toxicity. However, this study has 
been criticized since the interferon doses used in the 1-year 
comparison arm were substantially lower than those used 
in E1684. Since the efficacy of adjuvant interferon appears 
to be dose-dependent, it is possible that this trial compared 
two ineffective regimens. A trial of 4 weeks of high-dose 
adjuvant interferon versus placebo in patients with high 
risk melanoma is currently ongoing.44 Other studies have 
examined extended interferon regimens with treatment 
durations of 2–5 years, but none have used the standard-of-
care E1684 regimen as a comparator. For example, EORTC 
trial 18952 used interferon doses that were 50%–75% 
less than those used in E1684. With these lower doses, 25 
months of therapy appeared to be superior to 13 months, 
with a larger decrease in the risk of developing distant 
metastasis (7.2% vs 3.2%) and a modest survival benefit 
with the longer regimen.39 Extended courses of pegylated 
interferon also appear to be effective. EORTC trial 18991 
demonstrated an improved rate of relapse-free survival in 
patients receiving a 5-year course of pegylated interferon 
versus controls (45.6 vs 38.9%, P = 0.01).45 There was no 
significant difference in distant metastasis-free survival or 
overall survival between the two groups.
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GM-CSF
Recent studies suggest that adjuvant treatment with 
 granulocyte-macrophage colony stimulating factor (GM-
CSF or sargramostim) may also reduce the risk of mela-
noma recurrence in patients with resected disease with less 
 toxicity than interferon alpha-2b. GM-CSF is a  hematopoetic 
growth factor that also modulates immune system  activity 
in a variety of ways, mediating the proliferation and matura-
tion of  antigen-presenting dendritic cells46,47 and activating 
monocytes and macrophages.48,49 Spitler and colleagues 
tested a 3-year course of adjuvant GM-CSF in 98 patients 
with resected stage II(T4), III, or IV melanoma. The median, 
melanoma specific survival rate at 5 years in this cohort was 
60% overall and 67% and 40% for patients with resected 
stage III and resected stage IV disease respectively.50 The 
overall 5-year disease-free survival rate was 36%. In another 
trial at the Moffitt Cancer Center, 39 patients with resected 
stage IIIB, IIIC, or IV melanoma were treated with GM-CSF 
for 1 year with a median overall survival of 65 months and a 
median disease-free survival of 5.6 months.51 An increase in 
the number of mature dendritic cells in the peripheral blood 
was associated with remission or delayed recurrence. Based 
on these and other experimental data, the ongoing ECOG 
trial E4697 is comparing a 1-year course of GM-CSF, with 
or without melanoma-antigen peptide vaccination, to pla-
cebo in patients with high-risk node positive,  recurrent, and 
completely resected metastatic melanoma.52 As of  September 
of 2009, data from 735 patients were available, and patients 
treated with GM-CSF had a significantly longer DFS (11.8 
months) than patients not receiving GM-CSF (PFS 8.8 
months, P , 0.05).53
Other systemic adjuvant therapies
Melanoma is thought to be an immunogenic tumor, and a 
number of additional approaches toward boosting  antitumor 
immunogenicity have been tested in the adjuvant setting. 
Thus far, adjuvant trials of tumor vaccines derived from 
melanoma cells,54,55 cell lysates,56 and melanoma antigens 
including GM2 ganglioside,57 tyrosinase, gp-100, and 
MART-152 have failed to improve disease-free or overall 
survival in patients with resected melanoma. Ipilimumab is 
an anti-CTLA4 antibody designed to disinhibit antitumor 
immune responses with the goal of breaking the immune 
system’s tolerance to melanoma antigens. A phase II trial 
examined a 12-month course of ipilimumab with or without 
a multipeptide vaccine in patients with resected stage III and 
stage IV melanoma. At a median of 23 months follow-up, 
64% remained disease-free and only 9.3% of patients had 
died.58,59 A randomized phase 3 trial comparing adjuvant 
ipilimumab to placebo after resection of high-risk stage III 
melanoma is currently ongoing.60 Biochemotherapy, a com-
bination of multiple cytotoxic chemotherapy agents with 
immune modulators, was developed to overcome the relative 
treatment resistance of metastatic melanoma. A randomized 
phase III trial compared year-long high or intermediate dose 
adjuvant interferon regimens with 4 cycles of an adjuvant 
biochemotherapy regimen consisting of cisplatin, vinblastine, 
dacarbazine, interferon, and interleukin-2.61 There were no 
significant differences between the interferon and biochemo-
therapy groups with respect to median relapse-free or overall 
survival, but biochemotherapy was substantially more toxic 
then either interferon regimen. The trial was stopped due to 
futility after an interim analysis.
Treatment of loco-regionally 
advanced and in-transit disease
While local excision of isolated in-transit metastases is 
often feasible in patients with melanoma, more widespread 
regional cutaneous disease (Figure 1) may not be amenable 
to this approach. Several non-surgical modalities  including 
localized immune therapy, heated limb perfusion, and 
external beam radiation appear to confer reasonable rates of 
regional disease control in this setting.
Localized immune therapy
Localized administration of immune modulating agents has 
been shown to lead to regression of cutaneous  melanoma 
metastases in several phase II studies. In one study, 
 intralesional interleukin-2 given 2–3 times weekly was tested 
in 24 patients with one or more soft tissue or  cutaneous 
melanoma metastases yielding complete responses in 65% 
Figure 1 Unresectable melanoma in-transit metastases.
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of patients and partial responses in 21%.62  Recurrence of 
completely-regressed lesions was not observed, but the sub-
sequent development of visceral metastases was  common, 
occurring in 9 of 16 treated patients with stage III disease. 
Common and significant adverse events included pain at 
the injection site, local inflammation at the injection site, 
fever, flu-like symptoms, fatigue, nausea and vomiting. 
Intralesional interleukin-2 has also been given in combi-
nation with imiquimod, an agonist of toll-like receptor 7, 
with complete regression of 40.7% of 182 lesions treated, 
including cutaneous and subcutaneous lesions, and partial 
regression of 9.8%.63
Gene-based immunotherapy with electroporation is a 
novel approach to treating patients with cutaneous melanoma 
metastases. In a phase I dose escalation study, a plasmid 
 bearing DNA for IL-12, was injected into cutaneous mela-
noma lesions in 24 patients with stage III or IV disease. The 
injected lesions were then treated immediately with electropo-
ration using a circular array of electrodes.64 This  procedure 
was repeated on treatment days 1, 5, and 8. Intratumoral 
IL-12 expression assessed by enzyme-linked immunosorbant 
assay (ELISA) increased with increased plasmid dose, and no 
significant systemic toxicities were noted even at the highest 
plasmid dose tested. Nineteen of the 24 patients had distant 
metastases not treated with the plasmid or electroporation. Of 
this subgroup, two had complete responses with  regression 
of untreated lesions, and an additional patient achieved a 
CR after completion of electroporation and treatment with 
dacarbazine. Seven additional patients had stabilization of 
systemic disease after treatment. These results suggest that 
intratumoral electroporation of plasmid DNA encoding IL-12 
could lead to systemic antitumor immune responses with 
minimal systemic toxicity. Further studies of this treatment 
regimen are planned.
isolated limb perfusion
Isolated limb perfusion is a therapeutic option for the local 
management of cutaneous melanoma metastases isolated to 
one extremity. In this procedure, the major vascular structures 
are isolated, cannulated, and then attached to a bypass device so 
that therapeutic agents can be given to the extremity at doses 
that would be too high to tolerate if given systemically.65 In 
several retrospective studies, isolated limb perfusion using 
interferon, melphalan and TNF-alpha alone or in combination 
suggest complete response rates  ranging from 26% to 69% with 
partial responses in an  additional 25%–43%.66–68 Responses 
appear to be transient with  estimates of response duration and 
progression-free survival ranging from 9 to 12.4 months.66,67 
Long-term toxicities associated with isolated limb  perfusion 
include lymphedema, abnormal limb function, muscle  atrophy 
or fibrosis, neuropathy, persistent pain, and recurrent infec-
tion.69 Thus, isolated limb perfusion may be an option for 
patients with in-transit limb metastases, but there are significant 
toxicities.
external beam radiation
External beam radiation with hyperthermia provides an 
 additional therapeutic option for patients with  unresectable 
melanoma in-transit metastases. A 1995 prospective, 
randomized trial examined external beam radiation in 
70 patients with cutaneous, subcutaneous, or nodal mela-
noma. The 2-year local control rates for radiation with 
and without hyperthermia were 46% and 28% respectively 
(P , 0.05 based on univariate analysis).70,71
Systemic disease
Objective tumor responses are achieved only in a small 
minority of patients using standard-of-care therapies, and 
durable responses are uncommon. In addition, a recent meta-
analysis of over 2000 patients enrolled in phase II clinical 
trials found a median overall survival of 6.2 months.72 New, 
rationally based treatment approaches are currently under 
study, and options for enrollment in clinical trials should be 
presented to all patients with metastatic melanoma.
Limited stage iv disease
Surgical resection
There are several small case series describing patients with a 
limited extent of metastatic melanoma who had a relatively 
extended period of survival after resection of these tumors. 
In retrospective studies of highly selected patients, resec-
tion of isolated melanoma metastases in the liver and lung 
yielded median postoperative overall survival durations of 
19–28 months,73–75 which compare favorably to historical 
survival data for a general melanoma population. However, 
it is not clear whether lead time bias, selection bias, or surgi-
cal intervention was the primary determinant of survival in 
many of these studies. Adjuvant GM-CSF has been studied 
in patients with resected, stage IV disease as described in the 
adjuvant therapy section of this review.
immunotherapy for metastatic disease
interleukin-2
Interleukin-2 is a potent immune modulator that stimulates 
activation and proliferation of  T lymphocytes. Treatment with 
high-dose interleukin-2 leads to objective tumor responses 
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in a minority of patients, but a subset of reported complete 
responses have been durable. Overlapping, non-randomized 
trials, retrospective case series and meta-analyses of 100 or 
more patients with metastatic melanoma treated with high-
dose interleukin-2 have reported PR rates of 8.2%–10% and 
CR rates of 6%–6.6%.76–79 Sustained CRs have been reported 
in 4.4%–5.5% of patients.78,79 Patients with melanoma limited 
to subcutaneous tissue and those receiving more interleukin-2 
doses are more likely to have objective tumor responses.80 
Treatment with high-dose interleukin-2 typically is reserved 
for younger, fitter patients, and it requires intensive moni-
toring. High-dose interleukin-2 therapy is associated with 
substantial toxicity including hypotension, oliguria, renal 
insufficiency, hepatocellular damage, edema, respiratory 
compromise, fevers, chills, pruritis, diarrhea, myocardial 
infarction, sepsis, and death.
interleukin-2 with peptide vaccination
Recent data suggest that vaccination against the melanoma 
peptide antigen gp-100 may improve the efficacy of high 
dose interleukin-2. Preliminary reports from a randomized, 
multicenter phase III trial found a higher overall response 
rate in patients receiving interleukin-2 with a gp-100 peptide 
vaccine in comparison with patients receiving  interleukin-2 
alone (overall response rate = 22.1% vs 9.7%, P , 0.05).81 
Notably, the rate of response to interleukin-2 alone is consid-
erably lower than the overall response rate of approximately 
16% reported in previous studies,76–79 and a 2008 meta-
analysis of 3 phase II trials examining this interleukin-2 
vaccine combination reported an overall response rate of 
16% in 121 patients treated.82 A blinded review of the phase 
III response data was pending at the time these data were 
presented.
Anti-CTLA4 antibodies
The use of anti-CTLA4 antibodies in patients with 
advanced melanoma has emerged as a novel strategy for 
eliciting  effective antitumor immune responses. Antigen 
 presenting cells in the human immune system present anti-
gen  fragments on major histocompatibility complexes, and 
a second  surface protein, B7, acts as a costimulatory mol-
ecule for T  lymphocytes. The T-cell surface protein, CTLA4, 
 competes with CD28 for B7, and binding of CTLA4 to B7 
inhibits T-cell proliferation and the elaboration of immune 
 stimulatory cytokines. Thus anti-CTLA4 antibodies have 
been developed to abrogate these inhibitory interactions, 
favoring immune stimulation and in principle, breaking 
immune tolerance to melanoma.83
Clinical trials of the anti-CTLA4 ipilimumab in advanced 
melanoma have led to modest rates of objective tumor 
responses, but, thus far, registration trials of ipilimumab have 
failed to meet clinical end points required for the drug to be 
approved by the United States Food and Drug  Administration. 
Response rates to ipilimumab appear to be dose dependent. 
For example, in one trial, the objective response rate in 
patients receiving ipilimumab at doses of 0.3 mg/kg, 3 mg/kg, 
or 10 mg/kg were 0%, 4% and 11% respectively84 and higher 
doses were also associated with increased rates of prolonged 
stabilization of disease. A phase II registration trial of an 
ipilimumab regimen consisting of 10 mg/kg doses every 3 
weeks for 4 doses followed by maintenance infusions every 
12 weeks was tested in 150 patients and yielded an overall 
response rate of 5.8% with stabiliation of disease in an addi-
tional 21.3%.85 A recent meta-analysis of 3 phase II studies 
of ipilimumab, CA184-008, CA184-022, and CA184-007, 
examined overall survival in a pretreated population.86 A total 
of 487 patients were enrolled in the 3 trials and of those 
receiving 10 mg/kg doses of ipilimumab every 3 weeks for 
4 doses followed by maintenance infusions every 12 weeks, 
the median overall survival was greater than 10 months. 
Common toxicities observed with ipilimumab included 
grade 3 and 4 immune-related adverse events such as colitis, 
dermatitis, uveitis, enterocolitis, hepatitis, and hypophysitis. 
The incidence of immune-related adverse events has been 
correlated with clinical response.58,87,88 Latent responses to 
ipilimumab have been described, and it has been proposed 
that early evaluation of patients treated with this agent using 
RECIST criteria may not predict long-term clinical benefit 
from the drug.89 For example, in one study, 7 of 26 patients 
continued on ipilimumab despite progression of disease by 
RECIST criteria had latent tumor responses by a novel set of 
criteria deemed the immune-related response criteria.90
Ipilimumab has also been evaluated in combination 
with melanoma tumor vaccines, chemotherapeutics, and 
immune modulating agents. Based on data to date, the 
 addition of peptide vaccination to ipilimumab does not 
appear to improve response rates or survival.87,91 Recently, 
results were reported for a phase III trial comparing the 
safety and efficacy of the ipilimumab with or without 
gp-100 peptide vaccine versus gp-100 alone in patients 
with unresectable stage III or IV melanoma who had previ-
ously progressed on treatment regimens containing either 
dacarbazine, temozomide, fotemustine, carboplatin, or 
IL-2. Median overall survival was significantly improved in 
the group receiving ipilimumab alone versus gp-100 alone 
(10.1 vs 6.6 months).There was no difference in overall 
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survival when comparing the group receiving ipilimumab 
alone versus ipilimumab plus gp-100 (10.1  vs 10.0 
months).92 Initial reports suggest that combinations of ipili-
mumab with  chemotherapy warrant further investigation. 
A randomized phase 2 trial of ipilimumab with or with-
out dacarbazine found objective responses in 5.4% of 
patients treated with ipilimumab alone versus 17.2% of 
patients treated with  ipilimumab in combination with 
dacarbazine.93,94 Clinical benefit rates (CR + PR + SD) 
were 16.2% and 28.6% in patients treated without and with 
dacarbazine respectively. A large phase 3 trial is currently 
under way to assess the efficacy of dacarbazine with and 
without ipilimumab.95 Ipilimumab has also been combined 
with high-dose interleukin-2 with an objective response 
rate of 22% in 36 patients treated.96
Adoptive cell transfer
Adoptive cell transfer is a technique in which melanoma 
reactive lymphocytes are identified and expanded ex vivo 
and then re-infused into a patient in an effort to enhance 
antitumor immunity. Early trials examining this approach 
yielded high rates of initial objective tumor responses, but 
these responses were transient and infused tumor-infiltrat-
ing lymphocytes did not persist in the peripheral blood in 
significant titer.97,98 Subsequent trials utilized lymphocyte 
depletion prior to infusion of tumor infiltrating lymphocytes 
in order to reduce the mitigating effects of regulatory T-cells 
and to decrease competition for homeostatic cytokines.99 In 
a recent iteration of this approach, 93 patients were treated 
with a non-myeloablative preparatory regimen comprised of 
cyclophosphamide 60 mg/kg daily for 2 days followed by 
fludarabine dosed at 25 mg/m2 daily for 5 days.100  Subgroups 
of patients were also treated with either 2 Gy or 12 Gy of 
total body irradiation (TBI). 49% of unirradiated patients 
had objective tumor responses by RECIST criteria com-
pared with 52% of patients receiving 2 Gy of TBI and 72% 
of patients treated with 12 Gy. Tumor regressions at  visceral 
sites and in the brain were observed. Unlike in previous tri-
als, the expanded tumor-infiltrating lymphocyte clone was 
frequently detectable, often at high levels, in the peripheral 
blood months after the infusion, and such persistence was 
associated with tumor regression. It has been suggested that 
since tumor infiltrating lymphocytes can only be expanded 
in about half of patients,101 objective tumor response rates 
by intention to treat analysis would be 50% lower than the 
response rates reported above. Several trials of adoptive 
cell transfer in melanoma are currently accruing, including 
studies using tumor infiltrating lymphocytes,102,103 and a trial 
evaluating the antitumor efficacy of T-cells modified ex vivo 
to express the melanoma antigen MART-1.104
Chemotherapy for metastatic disease
Several cytotoxic chemotherapy agents have been shown to 
yield objective tumor responses or prolonged  stabilization 
of disease in advanced melanoma, but none has been 
proven to improve overall survival over best supportive 
care. The alkylating agent dacarbazine is the only cytotoxic 
agent approved by the FDA for the treatment of metastatic 
 melanoma, with reported objective response rates ranging 
from 5.5% to 20%.105–109 Sustained complete responses 
have been described in 1%–2% of patients treated with 
dacarbazine.110 Dacarbazine-based combination chemo-
therapy regimens, including cisplatin/vinblastine/dacar-
bazine111,112 and  cisplatin/dacarbazine/BCNU/tamoxifen,106 
generally confer increased toxicity without improvements 
in  progression-free or overall survival compared with 
dacarbazine alone.  Temozolomide is an orally bioavail-
able analog of dacarbazine with good central nervous 
system penetration that was compared head-to-head with 
dacarbazine in a phase III clinical trial yielding an overall 
response rate of 13.5% versus 12.1% for dacarbazine.107 
There were no differences between the two agents with 
respect to progression-free or overall survival, but a 
subsequent retrospective analysis did demonstrate fewer 
relapses in the central nervous system in patients treated 
with temozolomide.113
Alternatives to dacarbazine also include paclitaxel, a 
microtubule stabilizing agent, often with carboplatin. Phase 
II trials of paclitaxel monotherapy in chemotherapy naïve 
patients yielded objective response rates ranging from 
0% to 16.4%,114–116 and second-line trials of carboplatin 
with paclitaxel yield objective responses in 11%–36%.117 
Taxanes, such as paclitaxel, have poor penetration into the 
central  nervous system118 limiting their utility in patients 
with melanoma brain metastases, and they are susceptible to 
 chemotherapy resistance mechanisms such as over-expression 
of the multidrug resistance-1 drug transporter.119 Sagopilone 
is a fully-synthetic, third generation epothilone that evades 
the multidrug resistance-1 efflux pump120,121 and crosses the 
blood–brain barrier. Sagopilone has antitumor efficacy in 
a xenograft model of melanoma brain metastases122 and in 
clinical trials in patients with malignant glioma.123,124 A recent 
single-arm phase II trial of sagopilone in 35 patients with 
unresectable stage III and stage IV melanoma demonstrated 
one CR and three PRs in addition to stabilization of disease 
in eight additional patients.125
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Biochemotherapy was developed in an effort to 
overcome treatment resistance in metastatic melanoma. 
 Biochemotherapy, often combining cisplatin,vinblastine, 
dacarbazine, interferon, and interleukin-2, has been evaluated 
in metastatic melanoma in two phase III clinical trials126,127 
and a meta- analysis of 18 randomized trials involving 
2621 patients.128 While initial response rates were high 
(19.5%–33%), no study has documented significant survival 
benefits in comparison with conventional chemotherapy. One 
recent phase II study in 133 chemotherapy-naive patients with 
metastatic melanoma was designed to address the transience 
of responses to biochemotherapy by adding maintenance 
interleukin-2 to 4 cycles of biochemotherapy. As seen in prior 
studies, the initial overall response rate to biochemotherapy 
was high with complete responses in 8% of patients and  partial 
responses in 36% of patients.129 However, responses were 
again transient with a median progression-free survival was 
9 months and the median overall survival was 13.5 months.
Targeted therapy
Several oncogenic mutations have been identif ied in 
 cutaneous melanoma that may drive the malignant phenotype 
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by altering downstream signaling through the PI3K/AKT/
mTOR and MAP kinase pathways to decrease apoptosis130 
and increase cell cycling.131 Known oncogenic mutations in 
melanoma include NRAS mutations, found in 10%–15% of 
melanomas, loss of PTEN, observed in 10%–30%,130 c-KIT 
mutations seen in 23% of acral melanomas,132 and activating 
BRAF mutations, seen in 60%–80% of cutaneous  melanoma 
tumors (see Figure 2). Several agents targeting these 
molecular aberrations, including drugs targeting the c-KIT 
and BRAFV600E mutations, are currently being  evaluated in 
clinical trials.
Targeting the BRAFv600e mutation
Efforts to target the BRAFV600E mutation have now led to 
the development of a highly selective BRAF inhibitor that 
has shown tremendous promise in early clinical trials. Initial 
trials of RAF inhibitors in melanoma focused on sorafenib, 
a multi-kinase inhibitor targeting RAF, VEGF, and PDGF 
receptor tyrosine kinase signaling.133 However, a phase III 
trial comparing carboplatin and paclitaxel with and without 
sorafenib showed no differences between the two treatment 
groups with respect to the rate of objective tumor response, 
progression-free survival, and overall survival.117 PLX4032 
is a novel tyrosine kinase inhibitor engineered to have a high 
degree of specificity for mutant BRAFV600E. A phase I clinical 
trial presented at the 2009 Annual Meeting of the American 
Society of Clinical Oncology (ASCO) showed tumor regres-
sions in 5 of 7 known BRAFV600E positive melanoma patients 
treated at doses of at least 240 mg orally twice daily.134 In a 
separate presentation, this dose level was also determined 
to be minimum dose required for 90% inhibition of BRAF 
signaling as assayed using immunohistochemistry for 
phospho-ERK protein levels.135 An open-label phase II trial 
of PLX-4032 in patients with previously treated melanoma 
has recently completed accrual136 and a randomized phase III 
trial comparing single agent PLX-4032 with dacarbazine in 
the first-line setting is currently opening nationwide.137
Targeting c-KiT mutant melanoma
In a retrospective analysis of biopsy specimens from 189 
melanoma lesions, mutations of c-KIT exons 11, 13, and 17 
were observed in 1.7% of cutaneous melanomas, 23% of acral 
melanomas, and 15.6% of mucosal melanomas.132 Several 
small-molecule tyrosine kinase inhibitors that are approved 
by the FDA for other indications target c-KIT including 
sunitinib, imatinib, nilotinib, and dasatinib. Imatinib does not 
appear to be effective in an unselected population of patients 
with metastatic melanoma.138 However, in preliminary results 
from an ongoing phase II trial restricted to patients with 
tumors harboring somatic c-KIT mutations, imatinib dosed at 
400 mg twice daily induced partial tumor responses in three 
of five patients and the remaining two patients achieved pro-
longed stabilization of disease.139 Most patients required dose 
reductions for significant toxicities including gastrointestinal 
symptoms, rash, fatigue, and visual changes. In addition to 
the phase II imatinib trial, a case report describes 70% tumor 
shrinkage after treatment with sunitinib in a patient with 
metastatic mucosal melanoma bearing a mutation in KIT 
exon 11.140 In a recent report, the c-KIT mutation L576P was 
associated with resistance to multiple KIT inhibitors includ-
ing imatinib, nilotinib, and sorafenib, but objective tumor 
responses could be induced in 2 patients bearing the KIT 
L576P mutation after treatment with dasatinib.141 Currently, 
6 separate trials are testing c-KIT inhibitors in patients with 
melanoma arising from chronically sun-damaged skin, acral 
melanoma, mucosal melanoma, or documented c-KIT mutant 
melanoma.142–147
Central nervous system metastases
Radiation therapy for melanoma brain 
metastases
Brain metastases are a common cause of morbidity and 
mortality in patients with metastatic melanoma and radia-
tion therapy is the mainstay of treatment for patients with 
melanoma brain metastases. Whole brain radiation therapy 
for melanoma brain metastases appears to confer overall 
survival benefits in comparison with best supportive care. 
Based on retrospective data, patients with melanoma brain 
metastases treated with whole brain radiation therapy 
 survived 1 month longer than those undergoing observa-
tion only (overall survival 3.4 vs 2.1 months).148 Latent 
toxicities associated with whole brain irradiation include 
cognitive deficits, cerebrovascular disease, neuroendocrine 
dysfunction, and normal pressure hydrocephalus. Compared 
whole brain irradiation, stereotactic radiosurgery is associ-
ated with less post-procedural morbidity. However, retrospec-
tive analyses examining the effect of stereotactic radiosurgery 
may be prone to lead time bias, patient selection bias or 
other factors. Such studies found overall survival durations 
for patients with melanoma brain metastases treated with 
stereotactic radiosurgery ranging from 6 to 7.5 months.149–152 
One retrospective study that stratified for differences in age, 
number of brain lesions, and the presence of symptoms prior 
to treatment found a survival benefit of 7.3 months (P = 0.05) 
associated with gamma knife radiosurgery or surgical 
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excision when combined with whole brain irradiation in 
comparison to whole brain irradiation alone.153
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